Presolicitation
NOTICE OF INTENT TO SOLE SOURCE
75N96024Q00042
National Institutes of Health, National Institute of Health Niehs. Research and Development in Biotechnology (except Nanobiotechnology).
Response deadline
June 28, 2024 at 5:00 PM EDT
Closed 857 days ago. Posted June 13, 2024. Scheduled to archive July 13, 2024.
Get the next one like this from National Institutes of Health by email, the day it is posted.Find my opportunities
This one closed in 2024
18 like it are open now in research and development in biotechnology (except nanobiotechnology)
- Development/Production - Kidney GEC-Specific AAV Vector
Department of Veterans Affairs, Rpo East
Sources soughtNAICS 541714Columbia, MO36C24E27Q0009Closes in 2 daysNov 4 - AMPLICON SEQUENCING SERVICES
US Geological Survey, Ofc of Acquisition Grants-Denver
SolicitationNAICS 541714Location not published140G0226Q0047Closes in 3 daysNov 5 - High-throughput Unmasking of Biological Interactomes with Binding Landscape Emulators (HUBBLE)
Defense Advanced Research Projects Agency, Def Advanced Research Projects Agcy
SolicitationNAICS 541714Anywhere in the USDARPA-PA-27-01Closes in 4 daysNov 5
All 18 open in research and development in biotechnology (except nanobiotechnology)
Description
As published on SAM.gov.
The Division of Translational Toxicology (DTT) is an intramural division of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health. DTT uses traditional and cutting-edge approaches to better understand how factors in our environment may impact human health. Such approaches include identifying biomarkers of toxicity in different organs to evaluate the potential impacts of chemical agents of concern.
DTT requires support to generate robust summaries of transcriptional biomarkers of toxicity/disease in different tissues and organs. These summaries can then be used to characterize adversity in in vivo toxicity screens where gene expression is measured in a dose response format across multiple tissues. DTT is specifically interested in up/down-regulated organ/tissue transcriptional biomarkers of adversity (toxicity or disease) in mammalian models with an emphasis on rats.
Specific tissues for which biomarkers shall be identified and curated may include aorta, bone marrow, brain, cecum, colon, duodenum, epididymis, esophagus, eye, Harderian gland, heart, ileum, jejunum, kidney, liver, lung, lymph node, mammary gland, ovary, pancreas, parathyroid gland, peripheral nerve, pituitary, prostate, salivary gland, seminal vesicle, skeletal muscle, and skin.
Genes shall be identified with associated publications cited along with known eliciting agents (i.e., chemical treatments, dietary modifications, genetic models). Once a gene is identified, upstream mechanistic processes shall be curated to explain the response of each gene. The mechanistic curation shall ideally be organ/tissue specific but may also be more generalizable.
Publications
Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.
June 13, 2024
Presolicitation
Due June 28, 2024 at 5:00 PM EDT. SAM.gov, notice 5a9202a720d04056ab06855973cfa891
Points of contact
- ODESSA MCGLOWNODESSA.MCGLOWN@NIH.GOV9842873082
- Charlotte Angecharlotte.ange@nih.gov